Company profile: Wave Life Sciences
1.1 - Company Overview
Company description
- Provider of clinical-stage RNA medicines spanning RNA editing, antisense oligonucleotides, and RNA interference. Pipeline includes WVE-006 for alpha-1 antitrypsin deficiency, WVE-N531 for Duchenne muscular dystrophy, WVE-003 targeting the huntingtin gene to lower mutant huntingtin, and an INHBE program for obesity and metabolic disorders, advanced via the PRISM platform.
Products and services
- PRISM Platform: Proprietary platform combining RNA targeting modalities, chemistry innovation, and human genetics insights to develop RNA medicines
- WVE-006: RNA editing therapeutic correcting mutant SERPINA1 mRNA in alpha-1 antitrypsin deficiency to reduce liver disease and increase functional AAT protein
- WVE-003: Antisense oligonucleotide targeting SNP3 within the huntingtin gene to selectively lower mutant huntingtin protein while preserving wild-type huntingtin
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Wave Life Sciences
Immusoft
HQ: United States
Website
- Description: Provider of cell therapies for sustained therapeutic protein delivery in rare diseases, using its Immune System Programming (ISP) platform to modify patients’ B cells to produce proteins over extended periods. Pipeline includes ISP-001 for MPS I (alpha-L-iduronidase) and ISP-002 for MPS II (iduronate sulfatase).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immusoft company profile →
Chiasma
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions developing oral drugs for orphan diseases using proprietary Transient Permeability Enhancer technology to convert approved injectables to oral formulations, potentially enabling new indications and enhanced absorption by promoting delivery to the GI wall and liver.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chiasma company profile →
Minoryx Therapeutics
HQ: Spain
Website
- Description: Provider of pharmacological chaperone small-molecule drugs for genetic, neurometabolic, and rare pediatric diseases. Develops leriglitazone, a selective PPAR gamma agonist for X-linked adrenoleukodystrophy and other CNS diseases, supported by phase 2/3 results. Programs include ADVANCE (adult X-ALD), NEXUS (pediatric cALD), CALYX (adult progressive cALD), and a Friedreich's ataxia proof-of-concept.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minoryx Therapeutics company profile →
eTherapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development solutions using proprietary computational systems to analyze and predict medicine–cell interactions, optimizing efficacy and minimal side effects. Includes HepNet™ computational biology and GalOmic™ RNAi platforms, with candidates ETX-312 (MASH), ETX-407 (dAMD), ETX-148 (haemophilia), and ETX-291 (cardiometabolic).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTherapeutics company profile →
Vtesse Pharma
HQ: United States
Website
- Description: Provider of rare disease drug development for underserved patients, working collaboratively to advance VTS-270, which has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease; first spin-out of Cydan Development, Inc., an orphan-drug accelerator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vtesse Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Wave Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Wave Life Sciences
2.2 - Growth funds investing in similar companies to Wave Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Wave Life Sciences
4.2 - Public trading comparable groups for Wave Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →